Modulation of microRNAs by chemical carcinogens and anticancer drugs in human cancer: Potential inkling to therapeutic advantage

Molecular and Cellular Pharmacology

Volumn 3, Issue 3, 2011, Pages 135-141

  Haldar, Subrata ^a   Basu, Aruna ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Cancer; Chemical carcinogens; Chemopreventive agents; MicroRNAs

Indexed keywords

ANTINEOPLASTIC AGENT; AZOXYMETHANE; BENZYL ISOTHIOCYANATE; CARBAMIC ACID VINYL ESTER; CARCINOGEN; CAVEOLIN 1; CURCUMIN; DIHYDROXYBENZO[A]PYRENE OXIDE; DIMETHYLBENZ[A]ANTHRACENE; EPIGALLOCATECHIN GALLATE; ESTRADIOL; ESTROGEN RECEPTOR; GEMCITABINE; GENISTEIN; HISTONE DEACETYLASE INHIBITOR; ISOFLAVONE; METHYLNITROSOUREA; MICRORNA; RESVERATROL; RETINOIC ACID; SOMATOMEDIN BINDING PROTEIN 5; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; DIETARY INTAKE; DOWN REGULATION; DRUG SENSITIVITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; HUMAN; MALIGNANT TRANSFORMATION; NEOPLASM; NONHUMAN; PANCREAS CANCER; VEGETABLE;

EID: 84855438039     PISSN: None     EISSN: 19381247     Source Type: Journal    
DOI: 10.4255/mcpharmacol.11.18     Document Type: Article

References (59)

1. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genetics 2009;10:704-14.
2. Bhardwaj A, Singh S, Singh AP. MicroRNA-based cancer therapeutics: big hope from small RNAs. Mol Cell Pharmacol 2010;2:213-9.
3. Negrini M, Nicoloso MS, Calin GA. MicroRNAs and cancer--new paradigms in molecular oncology. Curr Opin Cell Biol 2009;21:470-9.
4. Dalmay T, Edwards DR. MicroRNAs and the hallmarks of cancer,. Oncogene 2006;25:6170-5.
5. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007;297:1901-8.
6. Szafranska AE., Davison TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007;26:4442-52.
7. Lee EJ, Gusev Y, Jiang J, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007;120:1046-54.
8. Basu A, Jiang X, Negrini M., Haldar S. MicroRNA-mediated regulation of pancreatic cancer cell proliferation. Oncol Lett 2010;1:565-8.
9. Kent OA, Mendell JT. A small piece in cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 2006;25:6188-96.
10. Cimmino A, Calin GA, Fabri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005;102:13944-9.
11. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ. MicroRNA-221/222 negatively regulates estrogen receptorα and is associated with tamoxifen resistance in breast cancer. J Biol Chem 2008;283:31079-86.
12. Fornari F, Gramantieri L, Ferracin M, et al. miR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008;27:5651-61.
13. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
14. Basu A, Alder H, Khiyami A et al. MicroRNA-375 and microRNA-221: Potential noncoding RNAs associated with antiproliferative activity of benzyl isothiocyanate in pancreatic cancer. Genes Cancer 2011;2:108-19.
15. Tellez CS, Juri DE, Do K et al. EMT and stem cell-like properties associated withmiR-205 and miR-200 epigenetic silencing are early manifestations during carcinogeninduced transformation of human lung epithelial cells. Cancer Res 2011;71:3087-97.
16. Mani SA, Guo W, Liao M-J, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
17. Gregory PA, Bracken CP, Bert AG, Goodall GJ. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 2008;7:3112-18.
18. Haque I, Mehta S, Majumder M et al. Cyr61/CCN1 signaling is critical for epithelialmesenchymal transition and stemness and promotes pancreatic carcinogenesis. Mol Cancer 2011;10:8.
19. Shen YL, Jiang YG, Greenlee AR et al. MicroRNA expression profiles and miR-10a target in anti-benzo[a] pyrene-7,8-diol-9, 10-epoxide-transformed human 16HBE cells. Biomed Environ Sci 2009;22:14-21.
20. Jiyang Y, Wu Y, Greenlee AR et al. miR-106a- mediated malignant transformation of cells induced by anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide. Toxicol. Sci. 2011;119:50-60.
21. Chen T. The role of microRNA in chemical carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2010;28:89-124.
22. Li Z, Branham WS, Dial SL et al. Genomic analysis of microRNA time-course expression in liver of mice treated with genotoxic carcinogen N-ethyl-N-nitrosourea. BMC Genomics 2010;11:609.
23. Yu T, Wang XY, Gong RG et al. The expression profile of microRNAs in a model of 7,12-dimethyl-benz[a] anthrance-induced oral carcinogenesis in Syrian hamster. J Exp Clin Cancer Res 2009;28:64.
24. Bhat-Naksharti P, Wang G, Collins NR et al. Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res 2009;37:4850-61.
25. Davidson LA, Wang N, Shah MS, et al. n-3 Polyunsaturated fatty acids modulate carcinogen-directed non-coding microRNA signatures in rat colon. Carcinogenesis 2009;30:2077-84.
26. Izzotti A, Calin GA, Arrigo P et al. Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. FASEB J 2009; 23:806-12.
27. Schembri F, Sridhar S, Perdomo C et al. MicroRNAs as modulators of smoking induced gene expression changes in human airway epithelium. Proc Natl Acad Sci USA 2009;106:2319-24.
28. Hsy PY, Deatherage DE, Rodriguez BA et al. Xenoestrogen-induced epigenetic repression of microRNA- 9-3 in breast epithelial cells. Cancer Res 2009;69:5936-45.
29. Moffat ID, Bourtros PC, Celius T et al. MicroRNAs in adult rodent liver are refractory to dioxin treatment. Toxicol Sci 2007;99:470-87.
30. Schetter AJ, Leung SY, Sohn JJ et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299:425-36.
31. Raver-Shapira N, Marciano E, Meiri E et al. Transcriptional activation of miR-34a contributes to p53- mediated apoptosis. Mol Cell 2007;26:731-43.
32. Melkamu T, Zhang X, Tan J, Zeng Y, Kassie F. Alteration of microRNA expression in vinyl-carbamate- induced mouse lung tumors and modulation by the chemopreventive agent indole-3-carbinol. Carcinogenesis 2010;31:252-8.
33. Dai Z, Barbacioru C, Huang Y, Sadee W. Prediction of anticancer drug potency from expression of genes involved in growth factor signaling. Pharm. Res 2006;23:336-49.
34. Dai Z, Huang Y, Sadee W. Growth factor signaling and resistance to cancer chemotherapy. Curr Top Med Chem 2004;4:1347-56.
35. Blower PE, Chung J-H, Verducci JS et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 2008;7:1-9.
36. Liu H, D'Andrade P, Fulmer-Smentek S, et al. mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol Cancer Ther 2010;9:1080-95.
37. Sun M, Estrov Z, Ji Y, et al. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol. Cancer Ther 2008;7:464-73.
38. Scott GK, Mattie MD, Berger CE, et al. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 2006;66:1277-81.
39. Garzon R, Pichiorri F, Palumbo T, et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 2007;26:4148-57.
40. Weidhaas JB, Babar I, Nallur, P, et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007;67:11111-6.
41. Davis CD, Ross SA. Evidence for dietary regulation of microRNA expression in cancer cells. Nutr Rev 2008;582:3542-6.
42. Qanungo S, Das M, Haldar S, Basu A. Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells. Carcinogenesis 2005;26:958-67.
43. Tsang WP, Kwok TT. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J Nutr Biochem 2010;21:140-6.
44. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003;23:363-98.
45. Safe S, Abdelrahim M. Sp transcription factor family and its role in cancer. Eur J Cancer 2005;41:2438-48.
46. Hoist F, Stahl PR, Ruiz C et al. Estrogen receptor a (ESR1) gene amplification is frequent in breast cancer. Nat Genet 2007;39:655-60.
47. Satake M, Sawai H, Go VL et al. Estrogen receptors in pancreatic tumors. Pancreas 2006;33:119-27.
48. Kundu JK, Surh YJ. Cancer chemopreventive and therapeutic potential of resveratol: mechanistic perspectives. Cancer Lett 2008;269:243-61.
49. Tili E, Michaille JJ, Alder H et al. Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGFβ signaling pathway in SW480 cells. Biochem Pharmacol 2010;80:2057-65.
50. Tili E, Michaille JJ, Adair B et al. Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis 2010;31:1561-6.
51. Li Y, VanderBoom TG, Kong D et al. Up regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabineresistant pancreatic cancer cells. Cancer Res 2009;69:6704-12.
52. Bianchini F, Vainio H. Isothiocyanates in cancer prevention. Drug Metabolism Reviews 2004;36:655-67.
53. Holst B, Williamson G. A critical review of the bioavailability of glucosinolates and related compounds. Natural product Reports 2004;21:425-47.
54. Zhang Y. Molecular mechanism of rapid cellular accumulation of anticarcinogenic isothiocyanates. Carcinogenesis 2001;22:425-31.
55. Basu A, Haldar S. Antiproliferative and proapoptotic effects of benzyl isothiocyanate on human pancreatic cancer cells is linked to death receptor activation and RasGAP/Rac1 down modulation. Int J Oncol 2009;35:593-9.
56. Avissar M, Christensten BC, Kelsey KT et al. MicroRNA expression is predictive of head and neck squamous cell carcinoma. Clin Cancer Res 2009; 15:2850-5.
57. Johnson SK, Haun RS. Insulin-like growth factor binding protein-5 influences pancreatic cancer cell growth. World J Gastroenterol 2009;15:3355-66.
58. Tanase CP. Caveolin-1: a marker for pancreatic cancer diagnosis. Expert Rev Mol Diagn 2008;8:395-404.
59. Formari F, Gramantieri L, ferracin M, et al. miR-221 controls CDKN1C.p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008;27:5651-61.